FMP
AN2 Therapeutics, Inc.
ANTX
NASDAQ
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
2.38 USD
-0.1 (-4.2%)
About
ceo
Mr. Eric E. Easom
sector
Healthcare
industry
Biotechnology
website
https://www.an2therapeutics.com
exchange
NASDAQ
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
CIK
0001880438
ISIN
US0373261058
CUSIP
037326105
Address
1800 El Camino Real
Phone
650-331-9090
Country
US
Employee
41
IPO Date
Mar 25, 2022
Summary
CIK
0001880438
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
037326105
ISIN
US0373261058
Country
US
Price
2.38
Beta
-0.24
Volume Avg.
478.18k
Market Cap
70.85M
Shares
-
52-Week
2.3699-22.22
DCF
0.66
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.87
P/B
-
Website
https://www.an2therapeutics.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ANTX News
It looks like there's no news available.
